Boothbay Fund Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Boothbay Fund Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,792	Closed	-$48.6K	–	2414
2023 Q1	$48.6K	Sell	15,792 -1,350	-8%	-$8.09K	﹤0.01%	2023
2022 Q4	$90.9K	Buy	+17,142	New	+$78.4K	﹤0.01%	1814
2021 Q3	–	Sell	-13,304	Closed	-$133K	–	2254
2021 Q2	$133K	Buy	+13,304	New	+$119K	﹤0.01%	1678
2021 Q1	–	Sell	-27,107	Closed	-$297K	–	1837
2020 Q4	$297K	Buy	27,107 +2,164	+9%	+$22.8K	0.01%	954
2020 Q3	$221K	Buy	+24,943	New	+$284K	0.01%	920

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Boothbay Fund Management's PSTX Position: Q2 2023 in Review

Boothbay Fund Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 15,792 shares — an estimated $48.6K sold.

Boothbay Fund Management first reported a position in PSTX in Q3 2020 and held it in 5 quarters. The position peaked at $297K in Q4 2020. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

Boothbay Fund Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 15,792 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $48.6K.
Boothbay Fund Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Boothbay Fund Management's Poseida Therapeutics, Inc. Common Stock position peaked at $297K in Q4 2020.
94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.